Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Shares Outstanding (Weighted Average) (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $8.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 7.64% year-over-year to $8.7 million, compared with a TTM value of $8.7 million through Sep 2025, up 7.64%, and an annual FY2024 reading of $7.8 million, up 84.05% over the prior year.
  • Shares Outstanding (Weighted Average) was $8.7 million for Q3 2025 at BioRestorative Therapies, up from $8.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $3.1 billion in Q2 2021 and bottomed at $788564.0 in Q3 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $319.0 million, with a median of $4.2 million recorded in 2023.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 361.88% in 2022, while the deepest fall reached 99.88% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $1.2 million in 2021, then soared by 204.6% to $3.6 million in 2022, then grew by 16.6% to $4.2 million in 2023, then soared by 84.05% to $7.8 million in 2024, then increased by 12.6% to $8.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BRTX at $8.7 million in Q3 2025, $8.6 million in Q2 2025, and $8.4 million in Q1 2025.